摘要
目的观察盐酸吡格列酮对2型糖尿病(T2DM)患者尿8-羟基脱氧鸟苷(8-OHdG)排泄的影响,探讨其肾脏保护作用的可能机制。方法 98例血糖控制欠佳的T2DM患者随机分为联合吡格列酮治疗组(A组)和磺酰脲类药物治疗组(B组)。12周后,观察治疗前后空腹血糖(FBG)、糖化血红蛋白(HbA1c)和尿白蛋白(ALB)、肌酐(Cr)及尿8-OHdG水平变化。结果①治疗12周后,A组FBG、HbA1c、尿ALB与Cr比(UACR)及尿8-OHdG与Cr比(U8CR)值较治疗前明显下降(P<0.01);B组FBG、HbA1c及U8CR值较治疗前明显下降(P<0.01),UACR值轻度降低,差异无统计学意义。②治疗后,两治疗组间FBG和HbA1c无明显差异,A组UACR及U8CR值较B组明显降低(P<0.05,P<0.01)。③U8CR水平与UACR呈正相关(r=0.755,P<0.01)。结论吡格列酮可以减少T2DM患者尿8-OHdG排泄,减轻体内氧化应激,该作用可能与其肾脏保护作用部分有关。
Objective To observe the effects of hydrochloride pioglitazone on urinary 8-hydroxy-deoxyguanosine （8-OHdG） excretion in type 2 diabetics and explore its possible reno-protective mechanisms. Methods 98 uncon- trolled type 2 diabetics were assigned randomly into group A （pioglitazone add-on） and group B （sulfonylureas add-on）. FBG, ttbAlc, urinary 8-OHdG urinary albumin （ALB） and urinary creatinine （Cr） were determined respectively after 12 weeks treatment. Results Compared with pre-treatment, FBG, HbAlc and urinary 8-OHdG/ Cr ratio（U8CR） were all obviously decreased in both therapy groups; urinary albumin/urinary creatinine ratio （UACR） markedly decreased in group A（P 〈0. 01 ）, while slightly decreased in group B（P 〉0.05） after twelve weeks observation. FBG and HbAlc showed no marked difference between group A and group B after treatment （P 〉0. 05）. UACR and U8CR in group A were significantly lower than those in group B（P 〈 0. 05,P 〈 0. 01 ）. Meanwhile, U8CR had positive correlation with UACR（r = 0. 755, P 〈 0. 01 ）. Conclusion Pioglitazone can de- crease urinary 8-OHdG excretion and lighten oxidative stress in vivo in type 2 diabetics, which may play a protective role in the kidney damage
出处
《安徽医科大学学报》
CAS
北大核心
2012年第12期1436-1438,共3页
Acta Universitatis Medicinalis Anhui
基金
安徽省卫生厅课题(编号:09A009)
